At a glance

Mazdutide Quick Reference

GLORY-1 target doses: Members only
Sign in to view dosing details.
Research route: SubQ injection
Clinical trials
Study duration: Members only
Sign in to view dosing details.
Research focus: Weight and glucose regulation
See cited research below

Overview

What Is Mazdutide?

Mazdutide, also called IBI362 or LY3305677, combines GLP-1 and glucagon receptor activity in one peptide. It is developed for chronic metabolic disease rather than a short bioregulator-style cycle. Its receptor pairing differs from tirzepatide’s GLP-1/GIP combination and retatrutide’s three-receptor approach.

In GLORY-1, 610 Chinese adults with overweight or obesity received weekly mazdutide or placebo. At 48 weeks, average weight change was −11.00% at 4mg and −14.01% at 6mg, versus +0.30% with placebo. GLORY-1 trial.

China approved mazdutide for chronic weight management in 2025. Later research includes diabetes and a higher 9mg target dose. Approval in one jurisdiction does not turn an unrelated research-market product into the studied medicine. China approval announcement.

Mechanism

Mazdutide Mechanism of Action

GLP-1 Receptor

GLP-1 activity supports satiety and glucose-dependent insulin signaling. Appetite reduction and lower energy intake contribute to the weight-management rationale.

Glucagon Receptor

The glucagon arm adds a pathway relevant to energy and substrate metabolism. Its contribution must be considered alongside GLP-1 activity, rather than assuming glucagon alone has the same metabolic effect.

Combined Glycemic Effect

DREAMS-1 evaluated mazdutide in adults with type 2 diabetes and reported better glycemic control than placebo. DREAMS-1 trial.

Long-Acting Exposure

Once-weekly clinical schedules allow sustained receptor activity. Dose escalation is part of tolerability management, not evidence that the target trial dose is an appropriate starting amount.

Research findings

Mazdutide Benefits

Results below describe studied populations and formulations. Trial endpoints and analyses matter when comparing outcomes.

Evidence: randomized human clinical trials

Weight Reduction

GLORY-1 showed substantial average weight reduction at both weekly target doses. Individual results and tolerability varied.

Higher-Dose Research

GLORY-2 studied a 9mg weekly target over 60 weeks. Mean weight change was −16.65% versus −1.50% with placebo under its treatment-policy analysis; this is a different study from GLORY-1. GLORY-2 trial.

Glucose Control

DREAMS-1 reported HbA1c changes of −1.57 and −2.15 percentage points at 4mg and 6mg, compared with −0.14 with placebo at week 24.

Cardiometabolic Measures

GLORY-1 reported improvements in prespecified cardiometabolic measures. Changes in risk markers do not by themselves prove fewer cardiovascular events.

Protocol planning

Mazdutide Dosing Protocol

Members Access Only

Sign in or create a free account to view this content.

Preparation

Mazdutide Reconstitution

Reconstitution Example

10mg vial + 2mL BAC water

Result5mg/mL

Reconstitution steps

1

Prepare

Wash your hands, clean the work surface, and wipe both vial stoppers with alcohol. Allow them to dry.

2

Add diluent slowly

Use a new sterile syringe and needle to direct the selected volume of compatible diluent down the inside wall of the vial.

3

Dissolve gently

Swirl or roll the vial until the contents dissolve; do not shake.

4

Storage

Store refrigerated at 2–8°C (36–46°F) and protected from light when the product instructions support this. Record the reconstitution date in your research journal.

N=1 reports

Mazdutide Community Experience

Self-reported anecdotal experiences aggregated from public & private peptide community discussions and anonymous peptideprotocols.app user reports. This information does not carry the same weight as published research.

Discussion & Research Interest

Appetite interest. The GLP-1 component makes appetite and food-intake changes a common focus of discussion.
Alternative receptor profile. Researchers compare the glucagon arm with tirzepatide and retatrutide.
Tracking opportunity. Weight, waist, intake, and GI symptoms are clearer observations than a claim of generalized metabolic improvement.

Limitations & Mixed Interpretation

Limited verification. Uncontrolled reports do not establish equivalence to clinical trial material.
GI tolerability. Nausea, diarrhea, and reduced intake can complicate interpretation of early weight changes.
Cross-trial comparisons. Different populations, durations, and estimands make simple rankings unreliable.

Stacking & synergy

Mazdutide Stacking & Synergy

The comparisons below are research context, not validated combination protocols. Overlapping receptor activity can add risk without demonstrated benefit.

Mazdutide + Retatrutide

A comparison rather than a routine combination: retatrutide adds GIP activity. Combining receptor agonists has no established benefit here and may compound tolerability problems.

Mazdutide + Tirzepatide

Tirzepatide pairs GLP-1 with GIP rather than glucagon. Both already have substantial metabolic activity; this is not an evidence-based additive stack.

Mazdutide + ATX-304

A distinct metabolic research concept. No controlled Mazdutide/ATX-304 combination data establish efficacy, compatibility, or safety.

Safety notes

Mazdutide Side Effects & Safety

Trial safety findings primarily concern gastrointestinal tolerability. They belong to the tested formulations, escalation schedules, and participants, and need to be interpreted in that context.

Adverse effects and interactions require evaluation for the exact compound and formulation.

Safety & Tolerability

Gastrointestinal effects, including nausea and diarrhea, are prominent in clinical studies.
Reduced appetite can make adequate nutrition more difficult.
Vomiting or persistent diarrhea can contribute to dehydration.

Unresolved Questions

Research-market vial quality is not established by clinical results for regulated formulations.
The safety of multi-agonist peptide stacks has not been established.
Broader long-term outcomes cannot be inferred solely from weight or biomarker changes.

Mazdutide Precautions

Avoid or discuss with a clinician if

Pregnancy or breastfeeding without appropriate medical guidance.
Known hypersensitivity to the formulation.
Severe persistent abdominal pain or repeated vomiting requires medical assessment.

Use caution with

Insulin or sulfonylureas, where changes in glucose control can require medication review.
Significant gastrointestinal disease, poor intake, dehydration, or complex metabolic treatment.

Research status: Mazdutide has China-specific approvals. This page does not imply approval of research-market vials or availability under the same rules in another country.

Final verdict

Peptide Protocols Verdict on Mazdutide

Not medical advice. This editorial is our own opinion piece based off the experience of our own lab rats.

Our opinionated opinion

Mazdutide is one of the more convincing additions to this library. It has moved beyond a receptor theory into meaningful randomized weight-loss and diabetes results. That is the kind of evidence that earns our attention.

The glucagon arm makes the comparison with tirzepatide and retatrutide interesting, but we would resist declaring a winner from separate trials. The population and study design matter as much as the headline percentage.

Our A reflects the clinical program, not a blanket endorsement of every product sold under the name. We see a strong metabolic candidate with a real evidence base and a clear need to respect tolerability.